Please assess the completion status of the following clinical trial:

Trial Title: HemaTrate™ in the Treatment of Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Critical Limb Ischemia in the study leg with ischemic rest pain and/or ulcer/minor tissue loss (Rutherford 4 or 5)~2. Previously failed an endovascular or surgical treatment of the study lower leg and is not being considered for additional intervention within the next 3 months OR is unsuitable for revascularization~Exclusion Criteria:~1. Simultaneously participating in another investigational study (e.g., drug or device)~2. Pregnant or breastfeeding, or planning to become pregnant within the next 12 months~3. Major surgery (open cardiac, vascular, or abdominal procedure) within the past 90 days~4. Endovascular intervention within the past 30 days~5. Current dialysis, or expected to need dialysis within the next 12 months~6. Previous above the ankle amputation in the study leg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
- Saline (Control Arm) (Type: PLACEBO_COMPARATOR): Patients assigned to the control arm will be injected with saline three times at six week intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).